MA39317A1 - Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe - Google Patents

Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe

Info

Publication number
MA39317A1
MA39317A1 MA39317A MA39317A MA39317A1 MA 39317 A1 MA39317 A1 MA 39317A1 MA 39317 A MA39317 A MA 39317A MA 39317 A MA39317 A MA 39317A MA 39317 A1 MA39317 A1 MA 39317A1
Authority
MA
Morocco
Prior art keywords
inhibitors
influenza virus
rna replication
virus rna
nucleoside derivatives
Prior art date
Application number
MA39317A
Other languages
English (en)
Inventor
Mark Smith
Klaus G Klumpp
Original Assignee
Riboscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riboscience Llc filed Critical Riboscience Llc
Publication of MA39317A1 publication Critical patent/MA39317A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des dérivés de nucléosides représentés par la formule i à utiliser en tant qu'inhibiteurs de la réplication d'arn du virus de la grippe. La présente invention concerne en particulier l'utilisation de dérivés de nucléosides de purine et de pyrimidine de formule i en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe ainsi que des compositions pharmaceutiques contenant de tels composés.
MA39317A 2014-02-06 2015-02-06 Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe MA39317A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461936569P 2014-02-06 2014-02-06
PCT/US2015/014762 WO2015120237A2 (fr) 2014-02-06 2015-02-06 Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe

Publications (1)

Publication Number Publication Date
MA39317A1 true MA39317A1 (fr) 2018-01-31

Family

ID=53774368

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39317A MA39317A1 (fr) 2014-02-06 2015-02-06 Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe

Country Status (20)

Country Link
US (2) US9370569B2 (fr)
EP (1) EP3102215B1 (fr)
JP (1) JP6581100B2 (fr)
KR (1) KR102327464B1 (fr)
CN (1) CN105979951B (fr)
AR (1) AR099312A1 (fr)
AU (1) AU2015213791B2 (fr)
CA (1) CA2945693C (fr)
CL (1) CL2016001973A1 (fr)
CR (1) CR20160400A (fr)
EA (1) EA033866B1 (fr)
IL (1) IL246929B (fr)
MA (1) MA39317A1 (fr)
MX (1) MX374191B (fr)
PE (1) PE20170203A1 (fr)
PH (1) PH12016501567B1 (fr)
SG (1) SG11201606368WA (fr)
TW (1) TWI620755B (fr)
WO (1) WO2015120237A2 (fr)
ZA (1) ZA201605979B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20160400A (es) * 2014-02-06 2016-11-07 Riboscience Llc Derivados de nucleosido sustituidos con 4´-difluorometilo como inhibidores de la replicación de arn de la influenza
RU2685230C2 (ru) 2014-02-06 2019-04-17 Хептарес Терапьютикс Лимитед Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN106478753A (zh) * 2015-09-16 2017-03-08 博瑞生物医药（苏州）股份有限公司 一种nuc‑1031单一异构体的制备方法和用途
CN111491634A (zh) * 2017-07-31 2020-08-04 詹纽瑞治疗公司 有机磷酸酯衍生物
CN111434671B (zh) * 2019-01-11 2023-07-11 凯思凯迪（上海）医药科技有限公司 肝脏特异性ampk激动剂及其制法和应用
JP2020164521A (ja) * 2019-03-29 2020-10-08 国立大学法人 長崎大学 抗ウィルス薬
JP2022522534A (ja) * 2019-04-02 2022-04-19 アリゴス セラピューティクス インコーポレイテッド Ｐｒｍｔ５を標的にする化合物
WO2020223530A1 (fr) * 2019-04-30 2020-11-05 Cure Biopharma Inc. Promédicaments à base de gemcitabine
WO2020227132A1 (fr) * 2019-05-03 2020-11-12 Terns, Inc. Composés pour traiter le cancer
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
AU2022256476B2 (en) 2021-04-16 2025-06-05 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
WO2022266384A1 (fr) * 2021-06-17 2022-12-22 Terns Pharmaceuticals, Inc. Méthodes de traitement du cancer
CA3228162A1 (fr) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Composes phospholipidiques et leurs procedes de production et d'utilisation
CN119546620A (zh) 2022-03-15 2025-02-28 罗梅治疗股份有限公司 用于治疗疾病的化合物和方法
WO2024103016A1 (fr) * 2022-11-11 2024-05-16 Rome Therapeutics, Inc. 4'-halométhyl-cytidine phosphoramidates et composés apparentés et leur utilisation dans le traitement d'affections médicales
CN119837893B (zh) * 2025-03-24 2025-07-04 中国农业大学 5-氟-2′-脱氧胞苷在制备抗菌药物中的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192749A (en) * 1990-05-21 1993-03-09 Syntex (U.S.A.) Inc. 4'-substituted nucleosides
KR20090089922A (ko) * 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US20040229840A1 (en) 2002-10-29 2004-11-18 Balkrishen Bhat Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
TW201305185A (zh) 2010-09-13 2013-02-01 吉李德科學股份有限公司 用於抗病毒治療之２’－氟取代之碳－核苷類似物
AU2011305652B2 (en) 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
KR102072041B1 (ko) 2011-12-22 2020-01-31 앨리오스 바이오파마 인크. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
NZ629996A (en) * 2012-03-13 2016-10-28 Gilead Sciences Inc 2’- substituted carba-nucleoside analogs for antiviral treatment
SI2827875T1 (sl) * 2012-03-21 2019-04-30 Alios Biopharma, Inc. Substituirani nukleozidi, nukleotidi in njihovi analogi
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MD20140134A2 (ro) 2012-05-22 2015-04-30 Idenix Pharmaceuticals, Inc. Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
US9243022B2 (en) 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
ES2952714T3 (es) * 2013-06-26 2023-11-03 Janssen Pharmaceuticals Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos
CN105829333A (zh) 2013-10-11 2016-08-03 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
CR20160400A (es) * 2014-02-06 2016-11-07 Riboscience Llc Derivados de nucleosido sustituidos con 4´-difluorometilo como inhibidores de la replicación de arn de la influenza

Also Published As

Publication number Publication date
ZA201605979B (en) 2024-10-30
PE20170203A1 (es) 2017-03-16
US20150225441A1 (en) 2015-08-13
HK1225617A1 (zh) 2017-09-15
US10092649B2 (en) 2018-10-09
TW201538517A (zh) 2015-10-16
AR099312A1 (es) 2016-07-13
CR20160400A (es) 2016-11-07
EA201691554A1 (ru) 2016-12-30
CN105979951B (zh) 2020-12-25
CL2016001973A1 (es) 2017-02-17
IL246929B (en) 2019-09-26
EP3102215A4 (fr) 2018-01-24
JP6581100B2 (ja) 2019-09-25
KR102327464B1 (ko) 2021-11-16
AU2015213791B2 (en) 2019-11-14
JP2017506229A (ja) 2017-03-02
KR20160145542A (ko) 2016-12-20
EP3102215A2 (fr) 2016-12-14
MX2016010105A (es) 2016-11-15
IL246929A0 (en) 2016-09-29
MX374191B (es) 2025-03-05
SG11201606368WA (en) 2016-09-29
CN105979951A (zh) 2016-09-28
CA2945693A1 (fr) 2015-08-13
EP3102215B1 (fr) 2021-06-16
TWI620755B (zh) 2018-04-11
WO2015120237A2 (fr) 2015-08-13
PH12016501567B1 (en) 2023-12-06
WO2015120237A3 (fr) 2015-11-05
US20170296664A1 (en) 2017-10-19
CA2945693C (fr) 2020-06-16
US9370569B2 (en) 2016-06-21
PH12016501567A1 (en) 2016-09-14
EA033866B1 (ru) 2019-12-03
AU2015213791A1 (en) 2016-09-08
NZ723551A (en) 2020-09-25

Similar Documents

Publication Publication Date Title
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
CL2017002155A1 (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MX389349B (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
MA42109A (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MX374191B (es) Derivados de nucleósido sustituidos con 4´ -difluorometilo como inhibidores de la replicación de arn de la influenza.
MX383124B (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus.
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA39374A1 (fr) Triterpénoïdes présentant une activité d'inhibition de la maturation du vih, substitués en 3ème position par un cycle non aromatique portant un substituant halogénoalkyle
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
MA38678A1 (fr) Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
MA41337A (fr) Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
CO6321288A2 (es) Sales de compuestos inhibidores de vih
MA40110B2 (fr) Dérivés de 7-(morpholinyl)-2-(n-pipérazinyl)méthylthiéno[2, 3-c]pyridine en tant que médicaments anticancéreux
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA39253B1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA38857B1 (fr) Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone
BR112015023560A8 (pt) Novos derivados de acrilamida como agentes antimaláricos